(S)-1-(4-(5-((4-(methylsulfonyl)morpholin-2-yl)methoxy)pyrido[3,4-b]pyrazin-7-yl)phenyl)ethanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (S)-1-(4-(5-((4-(methylsulfonyl)morpholin-2-yl)methoxy)pyrido[3,4-b]pyrazin-7-yl)phenyl)ethanone
• 英文别名: 1-[4-[5-[[(2S)-4-methylsulfonylmorpholin-2-yl]methoxy]pyrido[3,4-b]pyrazin-7-yl]phenyl]ethanone
• 化学式: C₂₁H₂₂N₄O₅S
• 分子量: 442.5
• InChiKey: BNXSCIYCNUCZQF-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  120
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (S)-1-(4-(5-((4-(methylsulfonyl)morpholin-2-yl)methoxy)pyrido[3,4-b]pyrazin-7-yl)phenyl)ethanone 、 二异丁基氢化铝 在 氮 、 氯化铵 、 水 、 二氯甲烷 、 Sodium sulfate-III 、 甲醇 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以to give 25 mg of title compound as white solid的产率得到1-(4-(5-(((S)-4-(methylsulfonyl)morpholin-2-yl)methoxy)pyrido[3,4-b]pyrazin-7-yl)phenyl)ethanol
  参考文献：
  名称：

  Substituted Pyridopyrazines as Syk Inhibitors

  摘要：

  本发明涉及式(I)的吡啶吡嗪化合物、其制药组合物和使用方法，其中R1、R2、R3、L、m、p和W如规范中所定义。

  公开号：

  US20160002221A1

文献信息

• SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS
  申请人：Hutchison Medipharma Limited

  公开号：EP2928888A1

  公开（公告）日：2015-10-14
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180071303A1

  公开（公告）日：2018-03-15

  The application provides methods reducing the side effects of chemotherapy and radiotherapy, including, hematopoietic toxicity, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis and alopecia. The application provides a method for increasing the number of, neutrophil counts and platelet counts in a patient in need thereof, comprising administering an effective of an inhibitor of spleen tyrosine kinase (SYKi). The present application provides methods for treating myelosuppresive disorders by the administration of a SYKi. In certain embodiments, the myelosuppression is induced by the administration of one or more myelosuppressive agents, for example, anti-cancer drugs. The present application provides methods for treating AML/ALL in a patient with 11q23/MLL abnormalities comprising the step of administering an effective amount of a SYKi to said patient.
• [EN] SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS<br/>[FR] PYRIDOPYRAZINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE SYK
  申请人：HUTCHISON MEDIPHARMA LTD

  公开号：WO2014086316A1

  公开（公告）日：2014-06-12

  The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, L, m, p and W are as defined in the specification.
• [EN] SYK INHIBITORS<br/>[FR] INHIBITEURS DE SYK
  申请人：GILEAD SCIENCES INC

  公开号：WO2018053189A2

  公开（公告）日：2018-03-22

  The application provides methods reducing the side effects of chemotherapy and radiotherapy, including, hematopoietic toxicity, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis and alopecia. The application provides a method for increasing the number of, neutrophil counts and platelet counts in a patient in need thereof, comprising administering an effective of an inhibitor of spleen tyrosine kinase (SYKi). The present application provides methods for treating myelosuppresive disorders by the administration of a SYKi. In certain embodiments, the myelosuppression is induced by the administration of one or more myelosuppressive agents, for example, anti-cancer drugs. The present application provides methods for treating AML/ALL in a patient with 11q23/MLL abnormalities comprising the step of administering an effective amount of a SYKi to said patient.